Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Earlier on Wednesday, Denmark's most valuable company, Novo Nordisk A/S NVO, reported second-quarter earnings that missed the analyst consensus.

Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets

Sales of weight-loss drug Wegovy and type 2 diabetes therapy Ozempic both missed expectations. A combination of supply shortages and competition are proving to be unexpected hurdles.

Why Shares of Wegovy Maker Novo Nordisk Are Tumbling Today

Novo Nordisk (NYSE:NVO) stock is falling on Wednesday after the pharmaceutical company announced results for the second quarter of 2024. A major blow to the company comes from its revenue of $3.8 billion.

NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?

Novo Nordisk A/S (NVO) Q2 2024 Earnings Conference Call August 7, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President, Head of North America Operations Martin Holst Lange - Executive Vice President, Head of Development Karsten Munk Knudsen - Chief Financial Officer Conference Call Participants Emily Field - Barclays Evan Seigerman - BMO Capital Markets Sachin Jain - Bank of America Richard Vosser - JPMorgan Peter Verdult - Citigroup James Quigley - Goldman Sachs Emmanuel Papadakis - Deutsche Bank Simon Baker - Redburn Atlantic Mark Purcell - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the First Six Months of 2024 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk A/S (NVO) Q2 2024 Earnings Call Transcript

Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.

Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On Ozempic, Wegovy

Novo Nordisk's (NVO) American depositary receipts (ADRs) slipped in pre-market trading Wednesday morning after rising sales of the company's weight-loss drugs failed to boost earnings to the level of growth analysts expected for the quarter.

Novo Nordisk Slides as Weight-Loss Drugs Fuel Less Growth Than Expected

Novo has helped to create a new market that should provide over 20% growth in the medium term. Three additional drivers for Novo include increasing obesity treatment capacity, insurance coverage, and the development of new pill-based obesity treatments. At 1.5x PEG I arrive at a YE25 price target of US$162 +29% upside potential.

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.

Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up

U.S. patients are staying on Novo Nordisk's Wegovy weight-loss medication for "around six months", an executive said on Wednesday, adding that the company is confident that over time as shortages ease that will increase to 12 months.

US patients staying on Wegovy obesity drug for 'around six months', Novo Nordisk says

Ozempic maker Novo Nordisk's (NYSE:NVO) weightloss drug sales were below expectations in the second quarter but this is not a significant concern, analysts said. Sales of Wegovy, the brand for semaglutide approved as a weightloss treatment, came in 14% below consensus, while sales of Ozempic, which is approved in the US for diabetes, were 3% lower than consensus forecasts.

Novo Nordisk's Wegovy miss 'will likely raise questions', says investment bank

Novo Nordisk is the leader in the glucagon-like peptide 1 (GLP-1) agonists market with 70% share. The company has notched some big wins with Wegovy this year, opening up several new billion-dollar markets.

Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?

Pharma giant Novo Nordisk on Wednesday reported booming demand for its weight loss and diabetes drugs Ozempic and Wegovy, but shares sank after the Danish firm disappointed investors with less-than-expected profits for the second quarter and a slimmed-down profit outlook for the year as it faces growing competition in the lucrative market and pressure to ease persistent supply constraints.

Ozempic Maker Novo Nordisk Sinks On Disappointing Earnings Amid Booming Demand For Weight Loss And Diabetes Drugs

Shares in Novo Nordisk (NYSE:NVO), the maker of weightloss and diabetes drugs Wegovy and Ozempic, fell over 5% after it slightly lowered the profit outlook for this year.  Operating profit for Europe's largest company by market valuation increased 18% in the second quarter of 2024 to 57.8 billion Danish krone (DKK), slower than the 27% growth seen in the first quarter.

Ozempic maker Novo Nordisk falls after cutting profit outlook

Novo Nordisk, Europe's largest company by market cap thanks to its wildly popular weight-loss drugs, managed just a small increase in second-quarter profits as it builds out the capacity to make the products.

Ozempic maker Novo Nordisk misses profit estimates as it builds out capacity

Novo Nordisk on Wednesday announced its second quarter earnings for 2024.

Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook

Novo Nordisk on Wednesday posted second-quarter operating profit below expectations, raised its 2024 sales forecast but cut profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.

Obesity drugmaker Novo Nordisk misses Q2 profit forecast

Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024 Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion. Operating profit is impacted by the impairment loss related to ocedurenone of DKK 5.7 billion.

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

Eli Lilly

Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.

Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look

Two more doses of Novo Nordisk's weight-loss drug, Wegovy, is now available, the U.S. Food and Drug Administration's updated shortages list showed on Tuesday.

US FDA says two more doses of Novo Nordisk's weight-loss drug now available

Amgen

Gilead Sciences

Viatris

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?

Lilly, Novo Nordisk battle for weight-loss market lands at the pharmacy shelf

Pharmacists have warned against buying fake weight loss jabs online as shortages of Ozempic persist in the UK. The National Pharmacy Association (NPA) said patients were risking their health over a possible “explosion in the unlicensed sale of medication online” on Monday.

Fake weight loss drugs spark warnings on Ozempic supply squeeze

A recent study compared the effectiveness of tirzepatide against semaglutide. Tirzepatide has been more effective in helping people lose weight in trials, and the study corroborated that.

Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug

Novo Nordisk (NVO) is set to report earnings for the second quarter on Wednesday morning after a first half in which the company's market of potential customers for its Ozempic and Wegovy weight-loss drugs expanded.

What You Need To Know Ahead of Novo Nordisk Earnings Wednesday

Viking Therapeutics

Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressable market.

News for Novo Nordisk Stock (NVO)